The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Open accessAbstract
BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation. METHODS: In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety. RESULTS: Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). CONCLUSIONS: Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan was associated with a 13.6% risk of interstitial lung disease (ILD)/pneumonitis, fatal in 2.2% of cases, which needed appropriate and rapid diagnosis and treatment.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan (DS-8201), an ADC composed of trastuzumab, a cleavable tetrapeptide-based linker and a cytotoxic topoisomerase I inhibitor, demonstrated a response rate of 60.6% (95% CI 53.4-68.0) and an unprecedented median PFS of 16.4 months (95% CI 12.7—not reached) in a phase II study of heavily pretreated patients (median six lines, range 2-27 lines, including trastuzumab and T-DM1).64”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 16,760
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., van de Vijver, M. J., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. O. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,190
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,163
Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009) · Clinical Medicine & Research · doi:10.3121/cmr.2009.825 · Cited by 1,023
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- 10.3121/cmr.2008.825 · DOI
- Modi S Tsurutani J Takahashi S et al. Safety and efficacy results from a phase 1 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2 expressing metastatic breast cancers. Presented at the 2017 San Antonio Breast Cancer Symposium San Antonio TX December 5–9 2017.
Cited by
Sorted by citations
Items 201–300 of 1,000
Soares, L. R., Vilbert, M., Rosa, V. D. L., Oliveira, J. L. M., de Deus, M. M., & Freitas‐Júnior, R. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101613 · Cited by 74
The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice
Claessens, A. K. M., Ibragimova, K. I. E., Geurts, S. M. E., Bos, M. E. M. M., Erdkamp, F., & Tjan‐Heijnen, V. C. G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102988 · Cited by 75
Targeting HER2 expression in cancer: New drugs and new indications
Vranić, S., Bešlija, S., & Gatalica, Z. (2020) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2020.4908 · Cited by 79
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Arora, S., Narayan, P., Osgood, C. L., Wedam, S. B., Prowell, T. M., Gao, J. J., Shah, M., Krol, D., Wahby, S., Royce, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2600 · Cited by 76
Systemic therapy for metastatic HER2-positive breast cancer
Bredin, P., Walshe, J. M., & Denduluri, N. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.008 · Cited by 77
Self-citationOhba, A., Morizane, C., Ueno, M., Kobayashi, S., Kawamoto, Y., Komatsu, Y., Ikeda, M., Sasaki, M., Okano, N., Furuse, J., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0214 · Cited by 73
An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy
Alharbi, K. S., Shaikh, M. A. J., Afzal, O., Altamimi, A. S. A., Almalki, W. H., Alzarea, S. I., Kazmi, I. A., Al-Abbasi, F. A., Singh, S. K., Dua, K., et al. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110108 · Cited by 73
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
Tateo, V., Marchese, P. V., Mollica, V., Massari, F., Kurzrock, R., & Adashek, J. J. (2023) · Pharmaceuticals · doi:10.3390/ph16040614 · Cited by 74
Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer
Andrikopoulou, Α., Zografos, E., Liontos, M., Koutsoukos, K., Dimopoulos, M. A., & Zagouri, F. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.08.006 · Cited by 71
Hingorani, D. V., Allevato, M. M., Camargo, M. F., Lesperance, J., Quraishi, M. A., Aguilera, J. A., Pietryga, I. F., Scanderbeg, D. J., Wang, Z., Molinolo, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31601-z · Cited by 73
Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
Aggarwal, D., Yang, J., Salam, M. A., Sengupta, S., Al-Amin, M. Y., Mustafa, S., Khan, M. A., Huang, X., & Pawar, J. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203073 · Cited by 71
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Stanowicka-Grada, M., & Senkus, E. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01137-5 · Cited by 75
Mitani, S., & Kawakami, H. (2020) · Cancers · doi:10.3390/cancers12020400 · Cited by 69
Antibody–Drug Conjugates for the Treatment of Breast Cancer
Corti, C., Giugliano, F., Nicolò, E., Ascione, L., & Curigliano, G. (2021) · Cancers · doi:10.3390/cancers13122898 · Cited by 69
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
CSCO BC guideline working group, Jiang, Z., Song, E., Geng, C., Pan, Y., Wang, X., Wang, H., Wang, S., Wang, X., Wu, J., et al. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-22-21 · Cited by 70
Chemical technology principles for selective bioconjugation of proteins and antibodies
Chauhan, P. S., Ragendu, V., Kumar, M., Molla, R., Mishra, S. D., Basa, S., & Rai, V. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00715d · Cited by 70
New drug approvals for 2019: Synthesis and clinical applications
Yuan, S., Yu, B., & Liu, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112667 · Cited by 68
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Wynn, C., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10021-x · Cited by 75
Zhang, J., Ji, D., Shen, W., Xiao, Q., Gu, Y., O’Shaughnessy, J., & Hu, X. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0456 · Cited by 68
Rethinking breast cancer follow-up based on individual risk and recurrence management
Rose, F. D., Meduri, B., Santis, M. C. D., Ferro, A., Marino, L., Colciago, R. R., Gregucci, F., Vanoni, V., Apolone, G., Cosimo, S. D., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102434 · Cited by 70
Kinneer, K., Wortmann, P., Cooper, Z. A., Dickinson, N. J., Masterson, L. A., Cailleau, T., Hutchinson, I., Vijayakrishnan, B., McFarlane, M., Ball, K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2630 · Cited by 68
McDermott, M. S. J., O’Brien, N. A., Hoffstrom, B., Gong, K., Lu, M., Zhang, J., Luo, T., Liang, M., Jia, W., Hong, J. J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2981 · Cited by 68
Poumeaud, F., Morisseau, M., Cabel, L., Gonçalvès, A., RIVIER, C. L., Trédan, O., Volant, E., Frenel, J., Ladoire, S., Jacot, W., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02766-9 · Cited by 68
Oberkampf, F., Gutierrez, M., Trabelsi‐Grati, O., Rhun, É. L., Trédan, O., Turbiez, I., Kadi, A., Dubot, C., Taillibert, S., Vacher, S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac180 · Cited by 71
Shah, M., Wedam, S. B., Cheng, J., Fiero, M. H., Xia, H., Li, F., Fan, J., Zhang, X., Yu, J., Song, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2701 · Cited by 67
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach
Sheng, J. Y.-S., Santa-Maria, C. A., Mangini, N. S., Norman, H., Couzi, R. J., Nunes, R., Wilkinson, M. J., Visvanathan, K., Connolly, R. M., Torres, E. T. R., et al. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00364 · Cited by 66
Shitara, K., Baba, E., Fujitani, K., Oki, E., Fujii, S., & Yamaguchi, K. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01196-3 · Cited by 69
Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment
Li, Y., Tsang, J. Y., Tam, F. K. Y., Loong, T., & Tse, G. M.-K. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104571 · Cited by 66
Yin, O. Q. P., Xiong, Y., Endo, S., Yoshihara, K., Garimella, T. S., Abutarif, M. A., Wada, R., & LaCreta, F. P. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2096 · Cited by 65
Beyond HER2: Targeting the ErbB receptor family in breast cancer
Drago, J. Z., Ferraro, E., Abuhadra, N. K., & Modi, S. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102436 · Cited by 65
Self-citationAdvances in medical treatment of breast cancer in 2022
Zhai, J., Wu, Y., Ma, F., Kaklamani, V., & Xu, B. (2023) · Cancer Innovation · doi:10.1002/cai2.46 · Cited by 67
Padmanabhan, R., Kheraldine, H., Meskin, N., Vranić, S., & Moustafa, A. A. (2020) · Cancers · doi:10.3390/cancers12030636 · Cited by 65
The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads
Boni, V., Sharma, M. R., & Patnaik, A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281107 · Cited by 64
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 64
Dri, A., Arpino, G., Bianchini, G., Curigliano, G., Danesi, R., Laurentiis, M. D., Mastro, L. D., Fabi, A., Generali, D., Gennari, A., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102672 · Cited by 64
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
Raghav, K. P. S., & Moasser, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0283 · Cited by 65
Management of infusion-related reactions in cancer therapy: strategies and challenges
Barroso, A., Estevinho, F., Hespanhol, V. P., Teixeira, E., Ramalho-Carvalho, J., & Araújo, A. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102922 · Cited by 63
Hamilton, E. P., Galsky, M. D., Ochsenreither, S., Conte, G. D., Martín, M., Miguel, M. J. D., Yu, E. Y., Williams, A., Gión, M., Tan, A. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1513 · Cited by 63
Self-citationRosso, C., & Voutsadakis, I. A. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.02.008 · Cited by 62
Abelman, R. O., Wu, B., Barnes, H., Medford, A., Norden, B., Putur, A., Bitman, E., Thant, W., Liu, T., Weipert, C., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2771 · Cited by 61
Weiss, M. C., Hibbs, J. E., Buckley, M. E., Danese, S. R., Leitenberger, A., Bollmann‐Jenkins, M., Meske, S. W., Ruiz, K. A., McHugh, T. W., Larson, S. L., et al. (2021) · Cancer · doi:10.1002/cncr.33906 · Cited by 63
Jia, Y., Kodumudi, K. N., Ramamoorthi, G., Basu, A. B., Snyder, C., Wiener, D. A., Pilon‐Thomas, S., Grover, P., Zhang, H., Greene, M. I., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.037 · Cited by 60
Self-citationThe Potential of Topoisomerase Inhibitor-Based Antibody–Drug Conjugates
Han, S., Lim, K. S., Blackburn, B. J., Yun, J., Putnam, C. W., Bull, D. A., & Won, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081707 · Cited by 60
Im, S., Gennari, A., Park, Y. H., Kim, J. H., Jiang, Z., Gupta, S., Fadjari, T. H., Tamura, K., Mastura, M. Y., Abesamis-Tiambeng, M. L. T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101541 · Cited by 62
Self-citationAntibody–drug conjugates in cancer therapy: mechanisms and clinical studies
He, J., Zeng, X., Wang, C., Wang, E., & Li, Y. (2024) · MedComm · doi:10.1002/mco2.671 · Cited by 60
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Henriques, B., Mendes, F., & Martins, D. F. (2021) · Biomedicines · doi:10.3390/biomedicines9111687 · Cited by 60
Wu, M., Huang, W., Yang, N., & Liu, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00347-1 · Cited by 59
Baez‐Navarro, X., Bockstal, M. V., Nawawi, D., Broeckx, G., Colpaert, C., Doebar, S. C., Hogenes, M. C. H., Koop, E. A., Lambein, K., Peeters, D. J. E., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100009 · Cited by 59
Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours
Zhang, J., Liu, R., Gao, S., Li, W., Chen, Y., Meng, Y., Liu, C., Jin, W., Wu, J., Wang, Y., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00522-5 · Cited by 59
Cavallaro, P. A., Santo, M. D., Belsito, E. L., Longobucco, C., Curcio, M., Morelli, C., Pasqua, L., & Leggio, A. (2023) · Nanomaterials · doi:10.3390/nano13172476 · Cited by 60
Neratinib for HER2-positive breast cancer with an overlooked option
Guo, L., Shao, W., Zhou, C., Yang, H. J., Yang, L., Cai, Q., Wang, J., Shi, Y., Huang, L., & Zhang, J. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00736-0 · Cited by 59
Biosynthesis of natural and halogenated plant monoterpene indole alkaloids in yeast
Bradley, S. A., Lehka, B. J., Hansson, F. G., Adhikari, K. B., Rago, D., Rubaszka, P., Haidar, A. K., Chen, L., Hansen, L. G., Gudich, O., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01430-2 · Cited by 59
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
Parit, S., Manchare, A., Gholap, A. D., Mundhe, P., Hatvate, N. T., Rojekar, S. V., & Patravale, V. B. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124211 · Cited by 59
Wang, J., Liu, Y., Zhang, Q., Li, W., Feng, J., Wang, X., Fang, J., Han, Y., & Xu, B. (2024) · 癌症：英文版 · doi:10.1002/cac2.12577 · Cited by 60
Huppert, L. A., Mahtani, R. L., Fisch, S. C., Dempsey, N. G., Premji, S., Raimonde, A., Jacob, S. L., Quintal, L., Melisko, M., Chien, J., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00748-5 · Cited by 59
Palle, J., Rochand, A., Pernot, S., Gallois, C., Taı̈eb, J., & Zaanan, A. (2020) · Drugs · doi:10.1007/s40265-020-01272-5 · Cited by 59
Tanaka, T., Okada, R., Hozaka, Y., Wada, M., Moriya, S., Satake, S., Idichi, T., Kurahara, H., Ohtsuka, T., & Seki, N. (2020) · Cancers · doi:10.3390/cancers12102731 · Cited by 58
Li, W., Guo, H., Li, L., Zhang, Y., & Cui, J. (2021) · Cancer Medicine · doi:10.1002/cam4.4052 · Cited by 59
Jie, J., Mao, D., Cao, J., Feng, P.-F., & Yang, P. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c10727 · Cited by 59
Kim, K., Hu, W., Audenet, F., Almassi, N., Hanrahan, A. J., Murray, K. S., Bagrodia, A., Wong, N. C., Clinton, T. N., Dason, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15885-7 · Cited by 59
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
Nadal‐Serrano, M., Morancho, B., Escrivá-de-Romaní, S., Morales, C. B., Luque-García, A., Escorihuela, M., Espinosa-Bravo, M., Peg, V., Dijcks, F. A., Dokter, W. H. A., et al. (2020) · Cancers · doi:10.3390/cancers12030670 · Cited by 57
Self-citationA Patent Review on FDA‐Approved Antibody‐Drug Conjugates, Their Linkers and Drug Payloads
Chia, C. S. B. (2022) · ChemMedChem · doi:10.1002/cmdc.202200032 · Cited by 57
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response
Bosi, C., Bartha, Á., Galbardi, B., Notini, G., Naldini, M. M., Licata, L., Viale, G., Mariani, M., Pistilli, B., Ali, H. R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113379 · Cited by 57
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Gandullo‐Sánchez, L., Capone, E., Ocaña, A., Iacobelli, S., Sala, G., & Pandiella, A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911498 · Cited by 56
Saini, K. S., Punie, K., Twelves, C. J., Bortini, S., de Azambuja, E., Anderson, S., Criscitiello, C., Awada, A. H., & Loi, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1936494 · Cited by 58
Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
Zimmerman, B. S., & Esteva, F. J. (2024) · Cancers · doi:10.3390/cancers16040800 · Cited by 56
Griguolo, G., Brasó‐Maristany, F., González‐Farré, B., Pascual, T., Chic, N., Saurí, T., Kates, R. E., Gluz, O., Martínez, D., Paré, L., et al. (2020) · Cancers · doi:10.3390/cancers12071902 · Cited by 56
What makes a good antibody–drug conjugate?
Cecco, M. D., Galbraith, D. N., & McDermott, L. L. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1880562 · Cited by 55
Yin, O. Q. P., Iwata, H., Lin, C., Tamura, K., Watanabe, J., Wada, R., Kastrissios, H., Abutarif, M. A., Garimella, T. S., Lee, C., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2291 · Cited by 55
Self-citationZhang, Y., Qiu, M., Wang, J., Zhang, Y., Shen, A., Yuan, X., Zhang, T., Wei, X., Zhao, H., Wang, D., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100814 · Cited by 55
Yao, H., Yan, M., Tong, Z., Wu, X., Ryu, M., Park, J., Kim, J. H., Zhong, Y., Zhao, Y., Voskoboynik, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02044 · Cited by 58
Self-citationYonesaka, K. (2021) · Cancers · doi:10.3390/cancers13051047 · Cited by 55
Adams, E., Wildiers, H. P. M. W., Neven, P., & Punie, K. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100204 · Cited by 54
Kuipers, H., de Bitter, T. J. J., de Boer, M. T., van der Post, R. S., Nijkamp, M. W., de Reuver, P. R., Fehrmann, R. S. N., & Hoogwater, F. J. H. (2021) · Cancers · doi:10.3390/cancers13215257 · Cited by 55
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
Retecki, K., Seweryn, M., Graczyk‐Jarzynka, A., & Bajor, M. (2021) · Cancers · doi:10.3390/cancers13236012 · Cited by 56
A role of FDG-PET/CT for response evaluation in metastatic breast cancer?
Hildebrandt, M. G., Naghavi‐Behzad, M., & Vogsen, M. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.03.004 · Cited by 55
Ruiz-Garcı́a, A., Baverel, P., Bottino, D. C., Dolton, M., Feng, Y., González-García, I., Kim, J., Robey, S., Singh, I., Turner, D. C., et al. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09850-2 · Cited by 54
Maiti, R., Patel, B., Patel, N., Patel, M. M., Patel, A., & Dhanesha, N. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01447-0 · Cited by 54
Rudin, C. M., Johnson, M. L., Paz-Ares, L. G., Nishio, M., Hann, C. L., Girard, N., Rocha, P., Hayashi, H., Sakai, T., Kim, Y. J., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-02142 · Cited by 54
Zhang, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107677 · Cited by 56
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
Barroso‐Sousa, R., & Tolaney, S. M. (2021) · BioDrugs · doi:10.1007/s40259-021-00472-z · Cited by 55
Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
Holloway, R. W., & Marignani, P. A. (2021) · Cancers · doi:10.3390/cancers13122922 · Cited by 56
Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer
Lee, J., & Park, Y. H. (2021) · Future Oncology · doi:10.2217/fon-2021-0550 · Cited by 53
Self-citationTapia, M., Hernándo, C., Martínez, M. T., Burgués, O., Tebar, C., Lameirinhas, A., Ágreda‐Roca, A., Torres‐Ruiz, S., Garrido‐Cano, I., Lluch, A. M., et al. (2023) · Cancers · doi:10.3390/cancers15184522 · Cited by 55
Phillips, G. D. L., Li, G., Guo, J., Yu, S., Fields, C. T., Lee, G., Zhang, D., Dragovich, P. S., Pillow, T. H., Wei, B. Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44533-z · Cited by 57
Self-citationSynthetic Approaches to the New Drugs Approved during 2019
Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Mahapatra, S., Carney, D. W., Lindsey, E. A., DeForest, J. C., France, S. P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00208 · Cited by 53
Desai, A. P., & Lovly, C. M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-708 · Cited by 55
Curigliano, G., Dunton, K., Rosenlund, M., Janek, M., Cathcart, J., Liu, Y., Fasching, P. A., & Iwata, H. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.04.516 · Cited by 52
Self-citationMcGuinness, J. E., & Kalinsky, K. M. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1840547 · Cited by 52
Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
Dent, S. F., Morse, A. M., Burnette, S., Guha, A., & Moore, H. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01114-x · Cited by 56
Li, H., Zhang, X., Xu, Z., Li, L., Liu, W., Dai, Z., Zhao, Z., Xiao, L., Li, H., & Hu, C. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab017 · Cited by 51
Torres, E. T. R., & Emens, L. A. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06423-0 · Cited by 51
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
Agostinetto, E., Montemurro, F., Puglisi, F., Criscitiello, C., Bianchini, G., Mastro, L. D., Introna, M., Tondini, C. A., Santoro, A., & Zambelli, A. (2022) · Cancers · doi:10.3390/cancers14092136 · Cited by 52
Kapil, A., Spitzmueller, A., Brieu, N., Haneder, S., Shumilov, A., Meier, A., Cecchi, F., Barkell, A., Harder, N., Mittermaier, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61957-9 · Cited by 51
Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates
Ascione, L., Guidi, L., Prakash, A., Trapani, D., LoRusso, P. M., Lou, E., & Curigliano, G. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_431766 · Cited by 53
Servetto, A., Formisano, L., & Arteaga, C. L. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188595 · Cited by 50
André, F., Cortés, J., Curigliano, G., Modi, S., Li, W., Park, Y. H., Chung, W.-P., Kim, S.-B., Yamashita, T., Pedrini, J. L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.08.2347 · Cited by 51
Self-citationBatista, M. V., Pérez-García, J. M., Garrigós, L., García-Sáenz, J. Á., Cortez, P., Racca, F., Blanch, S., Ruíz‐Borrego, M., Fernández-Ortega, A., Fernández-Abad, M., et al. (2024) · Med · doi:10.1016/j.medj.2024.08.001 · Cited by 50
Iida, K., Ahmed, A. H. A., Nagatsuma, A. K., Shibutani, T., Yasuda, S., Kitamura, M., Hattori, C., Abe, M., Hasegawa, J., Iguchi, T., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1434 · Cited by 50
The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
Kang, S., Gao, X., Zhang, L., Yang, E., Li, Y., & Yu, L. (2021) · Current Oncology · doi:10.3390/curroncol28020105 · Cited by 50
Self-citation
Metadata
- Authors
- Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., Sohn, J., Denduluri, N., Perrin, C., Aogi, K., Tokunaga, E., Im, S.-A., Lee, K. S., Hurvitz, S. A., Cortes, J., Lee, C., Chen, S., Zhang, L., Shahidi, J., Yver, A., & Krop, I.
- Affiliations
- SHOWA Medical University (JP)
- From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 610-621
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7458671
- OpenAlex
- W2996630100
- Cited by
- 2,006
- References
- 40
- Citations by year
- 2026: 234 · 2025: 266 · 2024: 317 · 2023: 355 · 2022: 345 · 2021: 312 · 2020: 174
- FWCI
- 86.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Daiichi-Sankyo
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- trastuzumab deruxtecan, HER2-positive breast cancer, metastatic breast cancer, trastuzumab emtansine, antibody-drug conjugates, previously treated patients, objective response rate, progression-free survival, neutropenia, dose escalation, topoisomerase I inhibitor, HER2-targeted therapy, treatment efficacy and safety
- MeSH terms
- Trastuzumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Camptothecin, Female, Humans, Middle Aged, Lung Diseases, Interstitial, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Kaplan-Meier Estimate, Intention to Treat Analysis, Consolidation Chemotherapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
